Cipla Past Earnings Performance
Past criteria checks 5/6
Cipla has been growing earnings at an average annual rate of 18.4%, while the Pharmaceuticals industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 9.2% per year. Cipla's return on equity is 15.5%, and it has net margins of 16.2%.
Key information
18.4%
Earnings growth rate
18.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 9.2% |
| Return on equity | 15.5% |
| Net Margin | 16.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Cipla makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 254,466 | 41,216 | 43,100 | 0 |
| 31 Dec 23 | 251,163 | 37,082 | 53,757 | 0 |
| 30 Sep 23 | 243,407 | 34,532 | 52,563 | 0 |
| 30 Jun 23 | 235,108 | 31,112 | 51,260 | 0 |
| 31 Mar 23 | 225,593 | 28,019 | 50,151 | 0 |
| 31 Dec 22 | 222,187 | 26,383 | 48,947 | 0 |
| 30 Sep 22 | 218,874 | 25,660 | 48,184 | 0 |
| 30 Jun 22 | 216,105 | 24,884 | 35,984 | 0 |
| 31 Mar 22 | 217,078 | 25,168 | 46,669 | 0 |
| 31 Dec 21 | 210,718 | 25,681 | 43,285 | 0 |
| 30 Sep 21 | 207,616 | 25,876 | 43,004 | 0 |
| 30 Jun 21 | 202,801 | 25,417 | 42,435 | 0 |
| 31 Mar 21 | 191,205 | 24,049 | 41,281 | 0 |
| 31 Dec 20 | 188,779 | 22,374 | 40,432 | 0 |
| 30 Sep 20 | 180,802 | 18,403 | 39,444 | 0 |
| 30 Jun 20 | 174,377 | 16,462 | 38,851 | 0 |
| 31 Mar 20 | 170,805 | 15,465 | 38,694 | 0 |
| 31 Dec 19 | 171,206 | 16,678 | 38,608 | 0 |
| 30 Sep 19 | 167,572 | 16,489 | 38,331 | 0 |
| 30 Jun 19 | 163,733 | 15,546 | 37,837 | 0 |
| 31 Mar 19 | 163,232 | 15,277 | 37,415 | 0 |
| 31 Dec 18 | 155,224 | 13,391 | 35,683 | 0 |
| 30 Sep 18 | 154,287 | 14,074 | 35,078 | 0 |
| 30 Jun 18 | 154,992 | 14,530 | 34,564 | 0 |
| 31 Mar 18 | 151,053 | 14,105 | 34,151 | 0 |
| 31 Dec 17 | 147,618 | 11,701 | 32,973 | 0 |
| 30 Sep 17 | 144,951 | 11,444 | 32,730 | 0 |
| 30 Jun 17 | 141,637 | 10,762 | 32,875 | 0 |
| 31 Mar 17 | 143,340 | 10,064 | 33,011 | 0 |
| 31 Dec 16 | 142,509 | 11,213 | 31,554 | 0 |
| 30 Sep 16 | 137,547 | 10,071 | 31,012 | 0 |
| 30 Jun 16 | 134,335 | 12,219 | 30,089 | 0 |
| 31 Mar 16 | 135,480 | 13,600 | 29,258 | 0 |
| 31 Dec 15 | 135,044 | 16,847 | 39,028 | 1,120 |
| 30 Sep 15 | 131,633 | 16,694 | 38,220 | 1,120 |
| 30 Jun 15 | 124,782 | 15,368 | 37,096 | 1,120 |
| 31 Mar 15 | 113,454 | 11,808 | 23,549 | 0 |
| 31 Dec 14 | 106,195 | 11,818 | 32,156 | 1,058 |
| 30 Sep 14 | 105,627 | 11,383 | 31,333 | 1,058 |
| 30 Jun 14 | 104,164 | 11,976 | 30,224 | 1,058 |
| 31 Mar 14 | 101,734 | 13,884 | 29,546 | 1,058 |
| 31 Dec 13 | 94,330 | 14,042 | 25,122 | 432 |
| 30 Sep 13 | 89,509 | 14,602 | 23,641 | 432 |
Quality Earnings: 500087 has high quality earnings.
Growing Profit Margin: 500087's current net profit margins (16.2%) are higher than last year (12.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 500087's earnings have grown by 18.4% per year over the past 5 years.
Accelerating Growth: 500087's earnings growth over the past year (47.1%) exceeds its 5-year average (18.4% per year).
Earnings vs Industry: 500087 earnings growth over the past year (47.1%) exceeded the Pharmaceuticals industry 18.2%.
Return on Equity
High ROE: 500087's Return on Equity (15.5%) is considered low.